Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. - Wikidata - awgldk - TriplyDB

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

http://www.wikidata.org/entity/Q37095348

about

TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors Clinical development of gene therapy: results and lessons from recent successes Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances Challenges and Opportunities for T-Cell-Mediated Strategies to Eliminate HIV Reservoirs Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine Immune Modulation in Hematologic Malignancies Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street The Evolution of T-cell Therapies for Solid Malignancies Adoptive T-cell therapy for cancer: The era of engineered T cells Developments in the treatment of hemophilia B: focus on emerging gene therapy T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect Progress and prospects for engineered T cell therapies T lymphocytes targeting native receptors Genetically modified T cells for the treatment of malignant disease HIV-1 functional cure: will the dream come true?Adoptive T-cell therapy for Leukemia Toxicities of Immunotherapy for the Practitioner To affinity and beyond: harnessing the T cell receptor for cancer immunotherapy Adoptive cell therapy for sarcoma Induced pluripotent stem cells in hematology: current and future applications Genetically modified T cells in cancer therapy: opportunities and challenges Computational Design of the Affinity and Specificity of a Therapeutic T Cell Receptor Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination Toxicity and management in CAR T-cell therapy Recent advances in T-cell engineering for use in immunotherapy T-cell receptor gene therapy--ready to go viral?TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity T cell engineering as therapy for cancer and HIV: our synthetic future Engineering T Cells to Functionally Cure HIV-1 Infection Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance T-Cell Receptor-Engineered Cells for the Treatment of Hematologic Malignancies.Structure of a TCR-Mimic Antibody with Target Predicts Pharmacogenetics.Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses Estimating the diversity, completeness, and cross-reactivity of the T cell repertoire.Engineered T cells for cancer treatment Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

P2860

Q21131200-73830D74-2E75-4116-B743-AC539D2C9647 Q26741260-4B836AFE-C857-4E76-9FEE-BD2B4B9BAB8F Q26743393-59D358D6-4DBE-42A7-915A-EFCE88A728F4 Q26773309-1B9A18DD-C9E1-4C12-B2F9-04AED9568940 Q26774669-AF36D85B-274C-4761-811A-1A84E17FCE61 Q26775720-6CBB6DBC-6CD2-409E-AF50-83389EC44843 Q26781511-FA512249-277F-4D1F-8CA4-7B04B4F654BA Q26782583-E5459340-A3BA-4E2A-9DF5-17A49C898161 Q26796307-F4D24566-45FD-4C96-9FE5-0A678F526CA1 Q26799357-D361DD1D-92C6-4BA3-991E-882FCBAD94E5 Q26799372-74DFC264-667A-4D4B-A41A-7A340DC29602 Q26800611-3ABAF14D-610E-4160-8AC5-73510DB281EC Q26823376-9424338B-1660-452F-B759-1AA155F79910 Q26826830-4D6D2850-D282-4677-93D7-C2DC164FDB65 Q26852923-CDFB7DC9-2472-488E-9B1B-27A6695DFAB4 Q26853345-57DEE332-56F0-4619-834B-8273782585F1 Q26860657-5B2BD714-9696-4EA4-B65C-930D5B1C0065 Q26865803-4049C69E-C8B1-4970-B64C-AC8B7F2FC57B Q27006934-4840CA3B-8136-48B9-92FC-F229721E7333 Q27008140-7E3DE739-8DFE-4CCD-9638-2A105C3D8C5A Q27008423-4C9DBFDE-20D7-48EF-94D2-9E7F893349B0 Q27009541-DBA839C8-AF95-4BEA-A725-346513A5B498 Q27016090-64ACEF97-C8A8-4D69-B6D7-F380FD43C3DF Q27026627-9A2142F8-FF0B-44AC-BC4D-6A697ADB82D3 Q27681832-6CB013CF-B33B-4BCB-ACB9-DF599E6F0F2C Q28068378-4806055D-835B-427F-8A72-75DB5009D0B0 Q28075314-A59FF4FB-88CF-464F-ABD9-C57CA9E36DAF Q28080312-3E0D4263-8B97-4EB7-9C2F-0F260D7A66F0 Q28081611-DC8C97F1-7CF3-4B83-ADBF-3017485B704B Q28081699-59C9D002-3B41-4BF1-AF12-E66EBCFEA511 Q28082253-DE9D7486-DF5A-443F-BDA7-C8F40ED19DAA Q28086801-02988A28-FB83-4EDF-AFB8-9E0107B03EA7 Q28269352-E8956184-AE9D-408C-A08F-44AFD60F2652 Q30251555-7A75719A-372C-41AE-9958-B6519BE18963 Q30382749-024254AB-C4C5-4912-AC8E-FD4E0001191E Q30591778-4CB05262-5CBC-49C3-BBBE-5FB2B4415EE7 Q30600094-9839D0BA-9945-40C8-92A2-06E088816CDE Q33357547-B2D22607-8F04-4AED-855B-E12EA8CF54B1 Q33578792-D3FD3B56-FB65-46CA-9C9C-AD03DEDDD0ED Q33588711-F004FF12-D30C-452C-B1D1-3884DE386319

P2860

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

http://www.wikidata.org/entity/Q37095348

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 14 June 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Cardiovascular toxicity and ti ...... cells in myeloma and melanoma.

@en

Cardiovascular toxicity and ti ...... cells in myeloma and melanoma.

@nl

type

label

Cardiovascular toxicity and ti ...... cells in myeloma and melanoma.

@en

Cardiovascular toxicity and ti ...... cells in myeloma and melanoma.

@nl

prefLabel

Cardiovascular toxicity and ti ...... cells in myeloma and melanoma.

@en

Cardiovascular toxicity and ti ...... cells in myeloma and melanoma.

@nl

P1433

Q37095348-74A85F88-BE68-4ADE-8B36-D07AB6EC7D32

P1476

Q37095348-346043D6-5054-4FF1-A3D7-A8A42C9A8072

P2093

Q37095348-1BCE5697-224A-4650-B9F7-1DE2ED1B8175

Q37095348-1CFF4E39-B2DE-4DC6-91F0-3C78D13A55A3

Q37095348-222CA67C-B8E6-4890-982F-904F98CA0572

Q37095348-230E9E21-E72C-4E74-99C4-C47E496DB294

Q37095348-325B2D8E-1CED-4790-A5C2-F23D9259C275

Q37095348-3B0D33C4-A560-4FF6-B056-E7D3C5D02395

Q37095348-3CD781E0-F123-4BEB-B321-27820A49D88C

Q37095348-59D8DBE3-4C3E-4176-A898-62CC956E1075

Q37095348-6C2255E6-13AA-4235-94CC-6EF64DAB7AF5

Q37095348-725F52B3-BDFB-406E-91F6-0C77EBF94CC1

P2860

Q37095348-01CFCB6C-9447-470B-8263-0D15DFCDE3A1

Q37095348-0BE475C8-AFA6-4CC9-988D-994746A44B46

Q37095348-15D05CDD-9B1B-49D2-A0D5-B078D803E90E

Q37095348-27C3BFAC-F653-4141-8317-21E6E2A64758

Q37095348-28133546-5D6A-4037-8B6A-C1C940830B44

Q37095348-2FF5C9FC-CEDD-4E1C-9A09-C9BFD5A11A48

Q37095348-38E2BCB0-E7EC-4B4F-A91E-3F6D4FCAA804

Q37095348-3E2341B7-CC8B-4AFC-A3AD-4DA2D48877C0

Q37095348-4592B35A-4461-421F-9ED5-9D928038FA9B

Q37095348-574E5D1C-18A1-4BCD-B439-BE32DEB60C9F

P304

Q37095348-CE673083-CC0F-4E17-916A-2E3C3420F00C

P31

Q37095348-31504D62-DA87-4364-8154-C77D1733E463

P356

Q37095348-01D763B7-AE67-4EC7-9D98-6D9730B8BC4A

P407

Q37095348-8A691603-DDB4-4F31-B0ED-A5DD52692A6C

P433

Q37095348-0166942F-F852-4231-AD46-1F9894CD2D46

P478

Q37095348-98246CC6-0064-4D8A-B9E6-0B5033B3FE1E

P50

Q37095348-900B1A19-8F4F-4782-8AC4-F75A8DE8A676

P577

Q37095348-DA29ACE1-3437-46E0-8A71-BF38953D62E3

P5875

Q37095348-465C6F7D-A347-4015-AAE1-43D30AF11784

P698

Q37095348-B9EBF252-B032-4BC7-B16A-28F52FADF8D6

P921

Q37095348-A3334C70-5001-4234-A182-3BBE1CB8F8ED

P932

Q37095348-A5CA3492-2D71-4DAD-AA2D-D2AFBE8E0DC6

P356

BLOOD-2013-03-490565

P1433

P1476

Cardiovascular toxicity and ti ...... cells in myeloma and melanoma

@en

P2093

Aaron P Rapoport

http://www.w3.org/2001/XMLSchema#string

Adam Bagg

http://www.w3.org/2001/XMLSchema#string

Alan D Bennett

http://www.w3.org/2001/XMLSchema#string

Andrew B Gerry

http://www.w3.org/2001/XMLSchema#string

Beatriz M Carreno

http://www.w3.org/2001/XMLSchema#string

Bent K Jakobsen

http://www.w3.org/2001/XMLSchema#string

Bruce L Levine

http://www.w3.org/2001/XMLSchema#string

Carl H June

http://www.w3.org/2001/XMLSchema#string

Dominic P Smethurst

http://www.w3.org/2001/XMLSchema#string

Edward A Stadtmauer

http://www.w3.org/2001/XMLSchema#string

P2860

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

Adoptive immunotherapy for cancer: harnessing the T cell response

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

Cancer/testis antigens, gametogenesis and cancer

Inducible apoptosis as a safety switch for adoptive cell therapy

Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

P304

863-871

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2013-03-490565

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

122

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-06-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

239732554

http://www.w3.org/2001/XMLSchema#string

P698

23770775

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

P932

3743463

http://www.w3.org/2001/XMLSchema#string